Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
ARRAY BIOPHARMA INC (ARRY) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/30/2019 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "Amended and Restated Certificate of Incorporation of Array BioPharma Inc.",
"Amended and Restated By-Laws of Array BioPharma Inc.",
"First Supplemental Indenture, between Array BioPharma Inc., Pfizer Inc. and The Bank of New York Mellon Trust Company, N.A"
06/17/2019 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Agreement and Plan of Merger, among Array BioPharma Inc., Pfizer Inc. and Arlington Acquisition Sub Inc",
"Amendment to the Amended and Restated Bylaws of Array BioPharma Inc.",
"Pfizer Inc. Investor Relations: Chuck Triano +1 733-3901 [email protected] Media Relations: Patricia Kelly +1 733-3810 [email protected] Array BioPharma Inc. Investor Relations: Andrea N. Flynn, Ph.D. Senior Director, Investor Relations & Corporate Communications +1 381-6600 [email protected] Media Relations: Erika Hackmann Y&R PR, Media Relations +1 538-3375 [email protected] June 17, 2019 6:45 a.m. EDT | 4:45 a.m. MDT Pfizer to Acquire Array BioPharma"
05/21/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF V600E -mutant Metastatic Colorectal Cancer - BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control - - BRAFTOVI + MEKTOVI + cetuximab reduced the risk of death by 48% versus control - - Potential to be the first chemotherapy-free, targeted regimen for metastatic CRC patients - - Array intends to submit these data for marketing approval in 2H19 - - Array will host a conference call today, Tuesday, May 21, 2019, at 9:00 am Eastern Time -"
05/07/2019 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019"
03/22/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/18/2019 8-K Regulation FD Disclosure
Docs: "BRAFTOVI ® in Combination with MEKTOVI ® and ERBITUX ® or panitumumab Recommended by the National Comprehensive Cancer Network ® Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer"
02/20/2019 8-K Quarterly results
02/05/2019 8-K Quarterly results
10/30/2018 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019 – Strong launch quarter for BRAFTOVI ® + MEKTOVI ® in U.S. with $14 million in net sales – – European Commission approves BRAFTOVI + MEKTOVI for advanced BRAF-mutant melanoma – – COLUMBUS Phase 3 Trial Overall Survival Results Published in the Lancet Oncology – – Cash, Cash Equivalents and Marketable Securities as of September 30, 2018 were $415 million –"
10/26/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to the Amended and Restated Certificate of Incorporation"
09/20/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Press release"
08/14/2018 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018"
08/10/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Array BioPharma Names Carrie S. Cox Chairman of"
08/07/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "News Release Array BioPharma Receives FDA Breakthrough Therapy Designation for"
07/27/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Press release"
07/26/2018 8-K Regulation FD Disclosure
06/27/2018 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Array BioPharma Announces FDA Approval of BRAFTOVI™ in Combination with MEKTOVI®"
06/25/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC"
06/04/2018 8-K Regulation FD Disclosure
Docs: "Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma – Combination of encorafenib and binimetinib achieved 33.6 month median overall survival – – Data shows limited use of post-trial immunotherapy across treatment groups – – Phase 3 COLUMBUS results selected for “Best of ASCO” – – Encore investor webcast presentation today at 11:15 a.m. Central Time –"
05/09/2018 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018 - June 30, 2018 PDUFA date for encorafenib and binimetinib NDAs in BRAF-mutant melanoma - - Encorafenib and binimetinib combination achieved a median overall survival of 33.6 months in patients with BRAF-mutant melanoma in Phase 3 COLUMBUS trial - - Combination of encorafenib, binimetinib and cetuximab demonstrated an 8 month median progression-free survival in patients with BRAF-mutant colorectal cancer in updated safety lead-in results from Phase 3 BEACON CRC trial - - Cash, Cash Equivalents and Marketable Securities as of March 31, 2018 were $440 million -"
02/06/2018 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018",
"Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial"
01/22/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Exhibit 99.1 Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial"
01/03/2018 8-K Quarterly results
12/04/2017 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture, by and between Array BioPharma Inc. and The Bank of New York Mellon Trust Company, N.A"
11/20/2017 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events
11/17/2017 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Exchange Agreement",
"Array BioPharma Announces Private Exchange of $107 Million of its 3.00% Convertible Senior Notes due 2020 for its 2.625% Convertible Senior Notes due 2024 and Shares of its Common Stock"
11/13/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "Press release announcing ARRY-382 / CSF1R clinical data presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting"
10/31/2017 8-K Quarterly results
10/27/2017 8-K Submission of Matters to a Vote of Security Holders
09/15/2017 8-K Quarterly results
09/12/2017 8-K Quarterly results
09/11/2017 8-K Quarterly results
09/08/2017 8-K Quarterly results
08/28/2017 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy